New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:25 EDTARIA, ARIA, ARIA, RXDX, RXDX, RXDX, RHHBY, RHHBY, RHHBY, PFE, PFE, PFE, PBYI, PBYI, PBYI, NVS, NVS, NVS, MRTX, MRTX, MRTX, MRK, MRK, MRK, INCY, INCY, INCY, EXEL, EXEL, EXEL, CLVS, CLVS, CLVS, BMY, BMY, BMY, AZN, AZN, AZN, TSRO, TSRO, TSROLeerink pharma and biotech analysts hold an analyst/industry conference call
Biotech and Pharmaceuticals Analysts provide updates on lung cancer, in conjunction with the upcoming ASCO Annual Meeting, on an Analyst/Industry conference call to be held on May 20 at 3 pm.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
November 16, 2015
12:28 EDTCLVSOn The Fly: Top stock stories at midday
Stocks on Wall Street were mixed at midday as markets around the world, most notably in Europe, held up better than may have been expected after the terrorist attacks in Paris. ECONOMIC EVENTS: In the U.S., stock futures were pointing to a higher open early this morning, showing a good amount of resiliency in the face of the events in France this weekend. However, the futures weakened following the release of manufacturing data from the N.Y. region, leading to a slightly lower open for the broader market. The Empire State index edged up to -10.74 in November, which was improved from the -11.4 reading for last month but below expectations for a -6.50 reading. In Asia, Japan's gross domestic product declined 0.8% in the third quarter, missing expectations for a 0.2% decrease and taking the nation's economy back into recession. COMPANY NEWS: Starwood Hotels & Resorts (HOT) found a buyer, but it was not the one that recent reports had been foreshadowing. Starwood and Marriott (MAR) announced a merger agreement under which the companies will create the world's largest hotel company. Starwood, which had been linked in media reports to a number of other potential buyers in the past, including Hyatt (H) most recently, fell 6% following the deal announcement, while Marriott shares slid fractionally. MAJOR MOVERS: Among the notable gainers was (JD), which rallied 9.5% after the company reported third quarter earnings. Also higher was CONSOL Energy (CNX), which gained 6% after Business Insider reported that Greenlight Capital's David Einhorn reiterated the company as his "best idea" while presenting at the Robin Hood investors conference. Among the noteworthy losers was SunEdison (SUNE), which fell over 6.5% after quarterly filings showed that at least two prominent hedge funds have exited or trimmed their stakes in the company. Also lower was Clovis (CLVS), which was down 70% after it announced that the FDA requested additional data for rociletinib. INDEXES: Near midday, the Dow was up 68.18, or 0.4%, to 17,313.42, the Nasdaq was down 5.62, or 0.11%, to 4,922.27, and the S&P 500 was up 6.19, or 0.31%, to 2,029.23.
12:21 EDTCLVSImmunoGen selloff on Clovis news unwarranted, says RBC Capital
Subscribe for More Information
11:47 EDTRXDXEli Lilly reports 8.4% passive stake in Ignyta
Subscribe for More Information
10:27 EDTCLVS, AZNGoldman puts Conviction Buy-rated Clovis under review
Subscribe for More Information
10:23 EDTAZN, CLVSClovis price target cut to $28 from $92 at Piper Jaffray
Piper Jaffray analyst Charles Duncan cut his price target for shares of Clovis Oncology (CLVS) to $28 from $92 after the company announced that rociletinib efficacy data matured and the number of patients with a confirmed response is lower than expected. The updated response rate may still ultimately be approvable, but it further hinders rociletinib's competitive positioning compared to AstraZeneca's (AZN) Targrisso, Duncan tells investors in a research note. The analyst pushed back his first rociletinib sales estimate to Q4 of 2016 and lowered the drug's peak penetration of the second line market from 25% to 45%. He reiterates a Neutral rating on Clovis. The stock is down 67%, or $66.93, to $32.50 in morning trading.
10:11 EDTCLVSHigh option volume stocks
Subscribe for More Information
09:59 EDTPFEOmega bought Valeant in Q3, sold some SuneEdison
Leon Cooperman's Omega Advisors gave a quarterly update on its stakes in a filing this morning, disclosing its positions as of September 30. NEW STAKES: Pfizer (PFE), Valeant (VRX) Walgreens Boots Alliance (WBA), TerraForm Global (GLBL), Cigna (CI). INCREASED STAKES: Google Class A (GOOGL), Facebook (FB), Delta Air Lines (DAL). DECREASED STAKES: SunEdison (SUNE), Shire (SHPG), Citi (C), KAR Auction (KAR), LyondellBasell (LYB). LIQUIDATED STAKES: McKesson (MCK), 21st Century Fox (FOXA), General Motors (GM), QEP Resources (QEP), eBay (EBAY).
09:19 EDTCLVSOn The Fly: Pre-market Movers
HIGHER: Nexvet Biopharma (NVET), up 16.8% after NV-01 study meets primary endpoint... Protalix BioTherapeutics (PLX), up 4.8% after announcing that it will conduct a Phase III clinical trial for PRX-102... Array Biopharma (ARRY), up 4.3% after announcing a commercialization collaboration with Pierre Fabre... Perrigo (PRGO), up 2.1% after being upgraded to Buy from Neutral at UBS. DOWN AFTER EARNINGS: Dillard's (DDS), down 11.7% after reporting quarterly results. ALSO LOWER: Clovis Oncology (CLVS), down 71.3% after the FDA requested additional clinical data for rociletinib... KaloBios Pharmaceuticals (KBIO), down 48.9% after announcing that it will wind down its operations... Starwood Hotels (HOT), down 6.3% after announcing that Marriott (MAR) will acquire the company... Marriott is down 2.4%... Five Below (FIVE), down 3.1% after being downgraded to Hold from Buy at Deutsche Bank.
09:10 EDTCLVSClovis volatility elevated into FDA requests added data for rociletinib
Subscribe for More Information
08:35 EDTMRKMerck to present Phase 2 hep C therapy data at The Liver Meeting
Subscribe for More Information
08:32 EDTAZN, CLVSClovis reopens, down 64% after FDA requests added data for rociletinib
AstraZeneca (AZN), which is at work on a drug similar to rociletinib, is up 2.5% in pre-market trading.
08:15 EDTTSROTESARO launches Varubi in U.S.
Subscribe for More Information
08:13 EDTCLVSClovis to resume trading at 8:30 am ET
Subscribe for More Information
08:10 EDTTSROTESARO announces launch of VARUBI in US
Subscribe for More Information
08:01 EDTCLVSClovis says FDA requests additional data for rociletinib
Subscribe for More Information
07:57 EDTCLVSClovis shares halted, news pending
Subscribe for More Information
07:24 EDTMRKSalomon to hold a conference
Subscribe for More Information
07:00 EDTBMYBristol-Myers announces data from Phase 3 ALLY-3+ trial for Daklinza
Bristol-Myers announced late-breaking data from the Phase 3 ALLY-3+ trial investigating a regimen of Daklinza in combination with sofosbuvir and ribavirin in genotype 3 hepatitis C patients with advanced fibrosis or cirrhosis, for treatment durations of 12 and 16 weeks. This patient population is one of the most difficult to treat, among whom sustained virologic response rates, or cure, have proved harder to achieve. The results show that 100% of patients in the advanced fibrosis cohort achieved SVR12 in both the 12- and 16-week arms of the study. SVR12 rates were 83% and 89% in patients with cirrhosis in the 12- and 16-week arms, respectively.
06:33 EDTPFEPfizer, Allergan deal brings focus on U.S. tax-inversion deals, Reuters says
Pfizer's (PFE) takeover bid for Allergan (AGN) has refocused financial markets over a potential move by the U.S. Treasury Department against tax-inversion deals, Reuters reported Friday. The outlook for such a move remained unclear on Friday, the report says. Reference Link
05:57 EDTAZNAstraZeneca urges UK for antibiotics investment shake-up, Financial Time says
AstraZeneca has urged the U.K. government to develop a new model for incentivizing investment in antibiotics, reports the Financial Times. In a letter to the Financial Times, the company said it has joined other "leading voices" in the life sciences sectory to implore Britain to go ahead with a new system rather than waiting for an international agreement. The company said a new payment model was needed that would reward companies' investments but without encouraging the over-use of antibiotics. Reference Link
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use